A Standard Heparin Nomogram for the Management of Heparin Therapy

Archives of Internal Medicine

Volumn 151, Issue 2, 1991, Pages 333-337

  Cruickshank, Moirra K ^a,b,c   Levine, Mark N ^a,b,d   Hirsh, Jack ^a,b   Roberts, Robin ^a,b   Siguenza, Margaret ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b HAMILTON HEALTH SCIENCES   (Canada)

^c Canadian Heart Foundation ^*  (United States)

^d Medical Research Council of Canada ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; THROMBOEMBOLISM;

AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPARIN; HUMAN; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGE; MONITORING, PHYSIOLOGIC; PARTIAL THROMBOPLASTIN TIME; SUPPORT, NON-U.S. GOV'T; THROMBOEMBOLISM; THROMBOLYTIC THERAPY;

EID: 0026022024     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.1991.00400020085018     Document Type: Article

References (12)

1. Hull R, Raskob G, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med. 1986;315:1109-1114.
2. Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med. 1972;287:324-327.
3. Hirsh J, Van Aken WG, Gallus AS, Dolery CT, Cade JF, Yung WL. Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation. 1976;53:691-695.
4. Chiu H, Hirsh J, Yung W, et al. Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosis. Blood. 1977;49:171-184.
5. Levine M, Hirsh J. Hemorrhagic complications of anticoagulant therapy. Semin Thromb Hemost. 1986;12:39-57.
6. Kaplan E, Meier D. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
7. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-170.
8. Fleiss JL. Statistical Methods for Rates and Proportions. 2nd ed. New York, NY: John Wiley & Sons Inc; 1981:19-32.
9. Fennerty A, Levine M. Non-biological factors in the day-to-day variation of heparin requirements. BMJ. 1989;299:1012-1013.
10. Salzman E, Deykin D, Mayer Shapiro R, Rosenberg R. Management of heparin therapy: controlled prospective trial. N Engl J Med. 1975;292:1046-1050.
11. Wheeler A, Jaquiss R, Newman J. Physician practices in the treatment of pulmonary embolism and deep vein thrombosis. Arch Intern Med. 1988;148:1321-1325.
12. Fennerty A, Thomas P, Backhouse G, et al. Audit of control of heparin treatment. BMJ. 1985;290:27-28.